Pulmonary Arterial Hypertension (PAH) is a debilitating condition characterized by increased blood pressure in the pulmonary arteries, leading to progressive heart failure and premature death. Current treatment options for PAH are limited, emphasizing the need for innovative therapies. Vilitra 40, primarily known for its efficacy in treating erectile dysfunction, has emerged as a potential candidate for PAH treatment. PAH involves the narrowing of pulmonary arteries, resulting in increased vascular resistance and right ventricular dysfunction. Existing treatments primarily target vasodilation to alleviate symptoms and improve exercise capacity. However, these therapies often have limited efficacy and significant side effects, necessitating the exploration of alternative approaches to PAH management.